MedTrace Logo

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism

NCT01889134 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2013-06-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether osteoprotegerin and RANKL (receptor activator of nuclear factor-κB ligand) are involved in bone remodeling in patients with primary hyperparathyroidism (PHPT), and whether alendronate may be useful in treatment of the patients with PHPT who are not treated with parathyroidectomy.

Conditions

  • Primary Hyperparathyroidism

Interventions

DRUG

Sedron (alendronate)

PROCEDURE

Parathyroidectomy

Sponsors & Collaborators

  • Ministry of Science and Higher Education, Poland

    collaborator OTHER_GOV

  • Wroclaw Medical University

    lead OTHER

Principal Investigators

  • Jadwiga W Szymczak, PhD, MD · Wroclaw Medical University (Poland)

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-06-30
Completion
2012-10-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889134 on ClinicalTrials.gov